A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
Latest Information Update: 17 Jan 2024
At a glance
- Drugs ADCT 901 (Primary)
- Indications Advanced breast cancer; Cholangiocarcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 04 Jan 2024 According to an ADC Therapeutics media release, the Company has decided to discontinue this program due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs.
- 04 Jan 2024 Status changed from recruiting to discontinued, according to an ADC Therapeutics media release.
- 08 Aug 2023 According to an ADC Therapeutics media release, study protocol amendment to explore different dosing schedules has been finalized and submitted to the FDA and will be submitted shortly to the regulatory authorities in Europe. Once IRB approved the protocol, the Company plans to advance to the next dosing level. The IHC assay is under final validation.